Pacific Glory Development

Pacific Glory Development is a strategic investment and development subsidiary of Sino Biopharmaceutical Limited, a leading innovative pharmaceutical group in China. The company serves as a primary vehicle for the parent organization's international business development, licensing activities, and global partnerships. A key focus of Pacific Glory is the advancement of novel therapeutic candidates, most notably through its collaboration with Graviton Bioscience to develop ROCK2 inhibitors for fibrotic and inflammatory diseases. By facilitating these cross-border agreements, the company bridges global biotechnology innovation with the extensive clinical and commercial infrastructure of Sino Biopharmaceutical. Pacific Glory is instrumental in executing the group's strategy to acquire and co-develop high-potential assets in areas such as oncology, hepatology, and respiratory medicine.